Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618245 | 0.89 | PTGS2 (0.39) | PTGS2ARCHEK2FYN | |
| SCHEMBL10189302 | 0.89 | PTGS2 (0.40) | PTGS2CHEK2FYN | |
| SCHEMBL10188981 | 0.85 | PTGS2 (0.49) | PTGS2CHEK2FYN | |
| SCHEMBL10188963 | 0.83 | FYN (0.38) | PTGS2ALDH1A1HPGDFYN | |
| SCHEMBL10188969 | 0.83 | PTGS2 (0.40) | PTGS2ARALDH1A1HSD17B10CHEK2 | |
| SCHEMBL619539 | 0.82 | MAPT (0.34) | PTGS2ALDH1A1HPGDFPR2FYN | |
| SCHEMBL12338653 | 0.80 | MEN1 (0.37) | ARALDH1A1HPGDHSD17B10CHEK2 | |
| SCHEMBL10188957 | 0.80 | PTGS2 (0.41) | PTGS2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10188964 | 0.79 | PTGS2 (0.48) | PTGS2CHEK2 | |
| SCHEMBL15159001 | 0.78 | HTT (0.36) | PTGS2ALDH1A1HPGDHSD17B10FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885AR 474/4885ALDH1A1 1872/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885AR 474/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.